Page 829 - ACCCN's Critical Care Nursing

806 I N D E X

medications for 225, 225t neurally-adjusted ventilatory assist New York Heart Association (NYHA) functional
nursing management for 224–226 (NAVA) 397t, 398 classification of heart failure 231,
physical examination and 217–218 neurogenic shock 461, 556–557 233t
PTCA for 223–224, 223f clinical manifestations of 556 New Zealand Bill of Rights 80
reperfusion therapy for 221–224 collaborative management for 556–557 New Zealand National Transplant Donor
support of patient and family 226 nursing practice in 556–557 Coordination 787
symptom control of 225–226 respiratory muscle innervation by cord New Zealand Nurses Organisations (NZNO),
thrombolysis, nursing care for 224 level 556t nurse-to-patient ratios 24
thrombolytic therapy 221–223 neuroglia 417, 419t NHMRC see National Health and Medical
myocardial ischaemia 215–216 neurohormonal response, to heart failure 228, Research Council
myocardial preservation 295 230 nine equivalents of nursing man power
myocardium 181–182 neurologic system, organ dysfunction in (NEMS) 30–32, 31t
myopathy, critical illness 58 569 NIPPV see non-invasive positive pressure
myosin filaments 183, 183f neurological assessment 431–440 ventilation
conscious state 431–434 NIPSV see non-invasive pressure support
ventilation
N arousal 431–433 NIRS see near-infrared spectroscopy
awareness 433
NAS see nursing activity scale corneal reflexes 434 nitric oxide (NO) 402, 787
nasal cannulae eye and eyelid movement 433 NIV see non-invasive ventilation
high-flow 382 eye and pupil 433 NO see nitric oxide
low-flow 382 facial symmetry 434 NOC see Nurses’ Observation Checklist
nasal intubation, vs oral intubation 385 limb movement 433–434 non-benzodiazepine sedative 136t
nasogastric tube sizes 689t oropharyngeal reflexes 434 non-invasive blood pressure monitoring
nasopharyngeal airways 383, 384f liver dysfunction and 519–520 197–198
nasopharyngeal aspirate (NPA) 344 liver transplantation and 524 non-invasive cardiac diagnostic tests, nursing
nasopharyngeal swab (NPS) 344 physical examination 431–435 care 210
National E-Health Transition Authority PTA scale 434–435, 435t non-invasive haemodynamic monitoring 195,
(NEHTA) 44 neurological dysfunction 445–449 212b
National Health and Medical Research Council autonomic nerve dysfunction 447 non-invasive positive pressure ventilation
(NHMRC) cerebral metabolism and perfusion (NIPPV) 389
ethics in research 89–90 alterations 447–449 non-invasive pressure support ventilation
on human research consent 82 cerebral ischaemia 447–448, 447f (NIPSV) 389–390
levels of evidence designation in studies of cerebral oedema 448 non-invasive ventilation (NIV) 389–392, 787
effectiveness 39, 40t extracellular (vasogenic) oedema 448 for children 694
outcome types 40, 40t hydrocephalus 448 complications from 391–392
National Statement on Ethical Conduct in intracellular (cytotoxic) oedema 448 failure detection 392
Human Research 82 intracranial hypertension 448–449, indications for 390–391, 390t
national triage scale (NTS) 582 449f–450f acute respiratory failure 390
NAVA see neurally-adjusted ventilatory assist in children 696–698 CHF exacerbation 390–391
near-death experiences 671–672 assessment 696 COPD exacerbation 390–391
near-drowning 612–614, 787 encephalitis 698 weaning 391
near-infrared spectroscopy (NIRS), for nervous meningitis 697–698, 697t initiation of 391
system assessment 440 seizures 696–697 interfaces and settings for 391
necrosis 787 consciousness 445–446 monitoring priorities 391, 391t
negligence 28–29, 787 in cognition 445–446 physiological benefits of 390
NEHTA see National E-Health Transition coma 445–446 terminology 389–390
Authority seizures 446 non-maleficence 79
NEMS see nine equivalents of nursing man motor function alterations 446–447 non-rapid eye movement (non-REM) 145–146
power sensory function alterations 446–447 non-REM see non-rapid eye movement
nephrologist 787 neurological therapeutic management non-ST elevation myocardial infarction (non-
nephron 480, 480f–481f 449–455 STEMI) 218
nephrotoxicity 484 cerebral perfusion and oxygenation non-STEMI see non-ST elevation myocardial
nervous system optimisation 449–455, 451t infarction
anatomy of 414–431 cerebral vasospasm prevention 454–455, non-steroidal anti-inflammatory drugs
autonomic see autonomic nervous system 454f (NSAIDs) 144, 145t
brain injury assessment see brain injury intracranial hypertension management see normothermia, for intracranial hypertension
assessment intracranial hypertension management 453
central see central nervous system management of 452 nosocomial infections 119–122
cerebral oxygenation assessment see cerebral neuromuscular alterations 467–470 see also hospital-acquired pneumonia
oxygenation Guillain-Barré syndrome 467–469 NP see nurse practitioner
components of 414–417, 415f aetiology of 467 NPA see nasopharyngeal aspirate
neuroglia 417, 419t clinical manifestations of 467–468 NPS see nasopharyngeal swab
neurons 414–415, 416f collaborative management 468–469 NSAIDs see non-steroidal anti-inflammatory
neurotransmitters 416–417 independent practice 468 drugs
synapses 415–417, 417t, 418f nursing practice 468 NTS see national triage scale
enteric 431 pathophysiology of 467 nuclear medicine studies 209–210
non-invasive assessment 439–440 myasthenia gravis 469–470 nurse practitioner (NP) 6, 586–587
cEEG 439 aetiology 469 research vignette
NIRS 440 clinical manifestations of 469 acute care 13b
TCD ultrasound 439 nursing practice 469–470 transitional role 617b–618b
parasympathetic 431, 432f pathophysiology of 469 nurse-initiated analgesia, in ED 586
peripheral see peripheral nervous system neuromyopathy, critical illness 58 nurse-initiated x-rays, in ED 586
physiology of 414–431 neurons 414–415, 416f nurse-led follow-up service 71, 71t
sympathetic see sympathetic nervous system neuropeptides 416 Nurses’ Observation Checklist (NOC) 146, 146t
neural regulation see hormonal and neural neuroprotection, for SCI 462 nurse-to-patient ratios 24, 25t
regulation in renal system neurotransmitters 416–417 nursing activity scale (NAS) 30, 31t–32t